Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
The investigators previously characterized a phenotype with non-suppressed glucagon at 120
minutes after standardized oral glucose load. This phenotype is associated with healthy
metabolic traits such as lower BMI, higher insulin sensitivity and lower liver fat content.
Glucagon is a pleiotropic hormone that, besides its main action on increasing endogenous
glucose production, also reduces appetite and increases basal energy expenditure. The aims of
this study are to i. detect functional differences in the appetite-related central nervous
system (CNS) areas between the suppressed and non-suppressed glucagon phenotype ii. mimick
the non-suppressed glucagon phenotype in those participants who suppress glucagon by
administering a very-low-dose glucagon infusion and retest them.